Skip to main content
. Author manuscript; available in PMC: 2013 Jul 15.
Published in final edited form as: Clin Cancer Res. 2012 May 15;18(14):3889–3900. doi: 10.1158/1078-0432.CCR-11-3182

Figure 3. DARPP-32 up-regulates BCL-xL expression in gastric cancer cells.

Figure 3

A) MKN-28/pcDNA3 and MKN-28/DARPP-32 cells were treated with vehicle or 200 ng/ml TRAIL for 24h. qRT-PCR results showed that BCL-xL mRNA level was significantly higher in DARPP-32-expressing cells than in control cells (p<0.01). B) MKN-45/DARPP-32-shRNA and MKN-45/control-shRNA cells were treated with vehicle or 200 ng/ml TRAIL for 24h. qRT-PCR results indicated that knocking down endogenous DARPP-32 led to a significant decrease in BCL-xL mRNA level relative to control cells (p<0.01). Results are representative of three experiments and shown as the mean ± SEM. C) Western blot analysis showed that BCL-xL protein levels were higher in DARPP-32-expressing cells than control cells. D) Western blot analysis indicated that knockdown of endogenous DARPP-32 led to down-regulation of BCL-xL protein levels irrespective of treatment with TRAIL.